News

Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year

ANNOUNCEMENT NO. 261 Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year According…

2 years ago

Teladoc Health to Announce First Quarter 2024 Financial Results

PURCHASE, NY, April 12, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care,…

2 years ago

Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton

Finalized Medicare reimbursement pathway for personal exoskeletons expands access for all eligible Medicare beneficiariesMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April…

2 years ago

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

-Adenosine clinical development pausedWESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company…

2 years ago

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based…

2 years ago

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremorBOSTON, April…

2 years ago

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2…

2 years ago

Notable Labs Reports 2023 Financial Results and Provides a Business Update

FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage…

2 years ago

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a…

2 years ago